Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234465 | 0.84 | CYP1A2 (0.36) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| SCHEMBL23566530 | 0.84 | CYP1A2 (0.36) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| SCHEMBL18528405 | 0.81 | PHF8 (0.39) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| SCHEMBL17234464 | 0.81 | MEN1 (0.33) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| SCHEMBL18528423 | 0.81 | MEN1 (0.33) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| SCHEMBL18528424 | 0.81 | MEN1 (0.33) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| SCHEMBL17234574 | 0.81 | PHF8 (0.39) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| Ompenaclid SCHEMBL8505593 | 0.78 | ALOX15 (0.35) | KDM4EKDM5CPHF8KDM2AHIF1A | |
| SCHEMBL14510738 | 0.77 | — | — | |
| SCHEMBL17234154 | 0.75 | HIF1A (0.38) | HIF1ACYP1A2CYP2D6HSD17B10LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | claimed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | claimed |
| WO-2025131957-A1 | DIAZINONE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-6184216-B1 | EFFECTIVE BOTH AS ANTIDIABETIC AGENT AND ANTIOBESITY AGENT | PHARMACIA & UPJOHN COMPANY | 2001-02-06 | — | — | US | disclosed |
| US-6177453-B1 | Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 2001-01-23 | — | — | US | disclosed |
| US-6166080-A | Aminoquanidine carboxylates for the treatment of obesity | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | disclosed |
| US-5955617-A | ALSO FOR TREATMENT OF IMPAIRED GLUCOSE TOLERANCE, OBESITY | PHARMACIA & UPJOHN COMPANY (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0912523-A1 | AMINOGUANIDINE CARBOXYLATE LACTAMS FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997044324-A1 | AMINOGUANIDINE CARBOXYLATE LACTAMS FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0793646-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016031-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | KDM4E 3385/4885KDM5C 3250/4885PHF8 4283/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | KDM4E 1519/4885KDM5C 2304/4885PHF8 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.